504 related articles for article (PubMed ID: 30738364)
1. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G
Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364
[TBL] [Abstract][Full Text] [Related]
2. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
Francini E; Yip S; Ahmed S; Li H; Ardolino L; Evan CP; Kaymakcalan M; Shaw GK; Kantoff PW; Taplin ME; Alimohamed NS; Joshua AM; Heng DYC; Sweeney CJ
Clin Genitourin Cancer; 2018 Apr; 16(2):130-134. PubMed ID: 29331381
[TBL] [Abstract][Full Text] [Related]
5. Sequencing of agents in castration-resistant prostate cancer.
Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
[TBL] [Abstract][Full Text] [Related]
6. [Monitoring of treatment for metastatic castration-resistant prostate cancer].
Hinz S
Aktuelle Urol; 2017 May; 48(3):225-229. PubMed ID: 28614883
[TBL] [Abstract][Full Text] [Related]
7. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
8. What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
Lebdai S; Basset V; Branchereau J; de La Taille A; Flamand V; Lebret T; Murez T; Neuzillet Y; Ploussard G; Audenet F
World J Urol; 2016 May; 34(5):617-24. PubMed ID: 26373956
[TBL] [Abstract][Full Text] [Related]
9. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
[TBL] [Abstract][Full Text] [Related]
10. Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.
Parente P; Parnis F; Gurney H
Asia Pac J Clin Oncol; 2014 Sep; 10(3):205-15. PubMed ID: 24750803
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A
Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
[TBL] [Abstract][Full Text] [Related]
12. New treatment options for patients with metastatic prostate cancer.
Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on treatment of metastatic castration-resistant prostate cancer.
Merseburger AS; Bellmunt J; Jenkins C; Parker C; Fitzpatrick JM;
Oncologist; 2013; 18(5):558-67. PubMed ID: 23671006
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
15. The third line of treatment for metastatic prostate cancer patients: Option or strategy?
Roviello G; Petrioli R; Laera L; Francini E
Crit Rev Oncol Hematol; 2015 Sep; 95(3):265-71. PubMed ID: 26052050
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of metastatic castration-resistant prostate cancer].
Caffo O
Recenti Prog Med; 2015 Jan; 106(1):35-9. PubMed ID: 25621779
[TBL] [Abstract][Full Text] [Related]
17. Treatment sequencing in metastatic castrate-resistant prostate cancer.
Sartor O; Gillessen S
Asian J Androl; 2014; 16(3):426-31. PubMed ID: 24675654
[TBL] [Abstract][Full Text] [Related]
18. Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
Bahl A
Eur J Oncol Nurs; 2013 Sep; 17 Suppl 1():S1-6. PubMed ID: 24461207
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
[TBL] [Abstract][Full Text] [Related]
20. Metastatic castration-resistant prostate cancer: time for innovation.
Tucci M; Scagliotti GV; Vignani F
Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
